Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical leader advancing next-generation peptide therapeutics, officially presented comprehensive top-line data from its 24-week RECLAIM Phase 2 clinical trial evaluating pemvidutide in adults diagnosed with moderate-to-severe alcohol use disorder (AUD) on November 5, 2026. Delivered as a prestigious Late-Breaking Oral Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026 in Denver, Colorado, the randomized, double-blind, placebo-controlled trial demonstrated that once-weekly subcutaneous administration of pemvidutide 2.4 mg achieved its primary efficacy endpoint by producing a statistically significant, profound reduction in heavy drinking days (HDD) per week compared to placebo, alongside achieving FDA-validated registrational secondary endpoints including zero HDD and significant shifts in World Health Organization (WHO) Drinking Risk Levels.
What Are the Quantifiable Upstream Metrics and Endpoints in Altimmune's RECLAIM Trial?
Safety monitoring confirmed a clean tolerability profile. Consistent with prior MASH cohorts, adverse events were predominantly transient, mild-to-moderate gastrointestinal occurrences, with zero cases of severe hypoglycemic shock, renal dysfunction, or drug-induced liver injury.
How Does Balanced GLP-1/Glucagon Co-Agonism Treat Both Addictive Craving and Hepatic Injury?
Pemvidutide's proprietary molecular architecture incorporates an engineered 1:1 balance between glucagon-like peptide-1 (GLP-1) and glucagon receptor activation.
Clinical addiction specialists noted that the dual-action profile of pemvidutide addresses both the psychological and physiological aspects of alcohol dependency. Compulsive alcohol consumption frequently induces metabolic dysregulation that impairs glucose homeostasis and accelerates liver steatosis, creating a cycle where physiological stress reinforces addictive behavior. By improving metabolic parameters while simultaneously reducing neural craving intensity, the therapeutic offers an integrated clinical strategy that supports sustained recovery.
Additionally, Altimmune is conducting exploratory pharmacogenomic analyses to identify patient subgroups that demonstrate the highest treatment response rates. Preliminary data suggests that individuals with specific genetic polymorphisms related to dopamine receptor expression may achieve greater reductions in heavy drinking days when treated with peptide co-agonists, paving the way for personalized therapeutic interventions in addiction psychiatry.
What Are the Transformative Implications for Global Addiction Medicine and Incretin Therapeutics?
The decisive clinical validation achieved in the RECLAIM study expands the frontiers of the global incretin class beyond cardiometabolic indications into mainstream neuropsychiatric addiction medicine.
Because the FDA previously verified reductions in WHO Risk Drinking Levels and complete abstinence from heavy drinking days as formal approval endpoints, Altimmune will request an End-of-Phase 2 regulatory conference with federal health authorities in early 2027. The company aims to finalize pivotal Phase 3 registrational protocols targeting commercial authorization for the estimated 15 million Americans suffering from alcohol dependency, fundamentally transforming addiction therapy through targeted peptide biotechnology.
